{
    "nct_id": "NCT04772989",
    "official_title": "A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination With AB122 in Participants With Advanced Malignancies",
    "inclusion_criteria": "* Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n* Male or female participants ≥ 18 years of age (or age ≥ regionally approved age of consent for participation in investigational clinical studies) at the time of signing the informed consent.\n* Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1\n* Adequate organ and marrow function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of trauma or major surgery within 28 days prior to the first dose of study treatment.\n* Prior treatment with an anti-TIGIT antibody.\n* Any active or prior autoimmune disease that required treatment within 3 years of the first dose of study treatment.\n* Prior chemotherapy, targeted small-molecule therapy, immunotherapy, or biologic agents, or use of other investigational drugs within 28 days before first dose of study treatment.\n* Discontinued prior immunotherapy for immune related adverse events with a high severity.\n\nNOTE: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "miscellaneous_criteria": ""
}